Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Common Equity (2016 - 2025)

ImmunityBio (IBRX) has disclosed Common Equity for 12 consecutive years, with -$499.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 2.14% to -$499.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$499.6 million, a 2.14% decrease, with the full-year FY2025 number at -$499.6 million, down 2.14% from a year prior.
  • Common Equity was -$499.6 million for Q4 2025 at ImmunityBio, up from -$524.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$158.6 million in Q2 2021 to a low of -$744.2 million in Q3 2024.
  • A 5-year average of -$469.8 million and a median of -$494.3 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 1202.89% in 2021, then increased 29.54% in 2025.
  • ImmunityBio's Common Equity stood at -$243.9 million in 2021, then plummeted by 84.42% to -$449.8 million in 2022, then plummeted by 30.26% to -$585.9 million in 2023, then grew by 16.53% to -$489.1 million in 2024, then decreased by 2.14% to -$499.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Common Equity are -$499.6 million (Q4 2025), -$524.3 million (Q3 2025), and -$569.8 million (Q2 2025).